ProPhase Labs Statistics
Share Statistics
ProPhase Labs has 41.88M
shares outstanding. The number of shares has increased by 56.58%
in one year.
| Shares Outstanding | 41.88M |
| Shares Change (YoY) | 56.58% |
| Shares Change (QoQ) | 25.13% |
| Owned by Institutions (%) | 12.68% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 57,873 |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 457.14K, so 1.51% of the outstanding
shares have been sold short.
| Short Interest | 457.14K |
| Short % of Shares Out | 1.51% |
| Short % of Float | 1.69% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.27 and the forward
PE ratio is 0.29.
ProPhase Labs's PEG ratio is
0.
| PE Ratio | -0.27 |
| Forward PE | 0.29 |
| PS Ratio | 2.13 |
| Forward PS | 0.3 |
| PB Ratio | 1.96 |
| P/FCF Ratio | -0.78 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ProPhase Labs.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95,
with a Debt / Equity ratio of 3.34.
| Current Ratio | 0.95 |
| Quick Ratio | 0.92 |
| Debt / Equity | 3.34 |
| Debt / EBITDA | -0.76 |
| Debt / FCF | -1.33 |
| Interest Coverage | -11.53 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $70,520.83 |
| Profits Per Employee | $-555,875 |
| Employee Count | 96 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 6.05 |
Taxes
| Income Tax | 7.2M |
| Effective Tax Rate | -17% |
Stock Price Statistics
The stock price has increased by -88.14% in the
last 52 weeks. The beta is -0.46, so ProPhase Labs's
price volatility has been lower than the market average.
| Beta | -0.46 |
| 52-Week Price Change | -88.14% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.79 |
| Relative Strength Index (RSI) | 45.62 |
| Average Volume (20 Days) | 10,199,875 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of 6.77M
and earned -53.36M
in profits. Earnings per share was -2.43.
| Revenue | 6.77M |
| Gross Profit | -150K |
| Operating Income | -38.63M |
| Net Income | -53.36M |
| EBITDA | -32.34M |
| EBIT | -38.98M |
| Earnings Per Share (EPS) | -2.43 |
Full Income StatementBalance Sheet
The company has 678K in cash and 24.57M in
debt, giving a net cash position of -23.89M.
| Cash & Cash Equivalents | 678K |
| Total Debt | 24.57M |
| Net Cash | -23.89M |
| Retained Earnings | -58.39M |
| Total Assets | 63.2M |
| Working Capital | -1.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -17.54M
and capital expenditures -906K, giving a free cash flow of -18.44M.
| Operating Cash Flow | -17.54M |
| Capital Expenditures | -906K |
| Free Cash Flow | -18.44M |
| FCF Per Share | -0.97 |
Full Cash Flow StatementMargins
Gross margin is -2.22%, with operating and profit margins of -570.59% and -788.24%.
| Gross Margin | -2.22% |
| Operating Margin | -570.59% |
| Pretax Margin | -625.26% |
| Profit Margin | -788.24% |
| EBITDA Margin | -477.64% |
| EBIT Margin | -570.59% |
| FCF Margin | -272.44% |
